Scientific Publications

CLINUVEL has conducted over 15 trials of SCENESSE® (afamelanotide 16mg) involving over 900 patients, published research from which can be purchased online.

Below is a selection of published research on SCENESSE®. These links direct you to sites outside of the control of CLINUVEL which are not produced or endorsed by CLINUVEL.

Sancar, F. (2019). First Treatment for Rare Photosensitivity. Jama, 322(19), 1854-1854.
McNeil, M. M., Nahhas, A. F., Braunberger, T. L., & Hamzavi, I. H. (2018). Afamelanotide in the Treatment of Dermatologic Disease. Skin therapy letter, 23(6), 6.
Lane, A. M., McKay, J. T., & Bonkovsky, H. L. (2016). Advances in the management of erythropoietic protoporphyria–role of afamelanotide. The application of clinical genetics, 9, 179.
Minder, E. I., Barman-Aksoezen, J., & Schneider-Yin, X. (2017). Pharmacokinetics and pharmacodynamics of afamelanotide and its clinical use in treating dermatologic disorders. Clinical pharmacokinetics, 56(8), 815-823.
Rodrigues, M., Ezzedine, K., Hamzavi, I., Pandya, A. G., Harris, J. E., & Vitiligo Working Group. (2017). Current and emerging treatments for vitiligo. Journal of the American Academy of Dermatology, 77(1), 17-29.
Langendonk J, Balwani M, Anderson K et al (2015). “Afamelanotide for Erythropoietic Protoporphria”. New Eng J Med. 373(1):48-59.
Biolcati G, Marchesini E, Sorge F et al (2015). “Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.” Br J Dermatol. 172(6):1601-1612. E-Pub Dec 13, 2014. Available online:
Minder E & Schneider-Yin X (2014). “Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria”. Expert Rev Clin Pharmacol. 7(6).
Lim HW, Grimes PE, Agbai O, et al (2014). “Afamelanotide and Narrowband UV-B Phototherapy for the Treatment of Vitiligo”. JAMA Dermatol. E-Pub Sept 17.
Biolcati G et al (2013). “Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey–Hailey disease.” Clin Exp Dermatol. E-Pub 25 Oct.
Fabrikant J, Touloei K & Brown SM, (2013). “A Review and Update on Melanocyte Stimulating Hormone Therapy: Afamelanotide”. J Drugs Dermatol. 12(7):775-779.
Bohm M, Ehrchen J & Luger TA, (2012). “Beneficial effects of the melanocortin analogue Nle(4) -d-Phe(7) -α-MSH in acne vulgaris.” JEADV. E-Pub July 27.
Haylett AK, Nie Z, Brownrigg M, Taylor R, E Rhodes L, (2010). “Systemic photoprotection in solar urticaria with α-melanocyte stimulating hormone analogue [Nle(4) -D-Phe(7) ]-α-MSH.” Br J Dermatol. 164(2):407-14.
Minder, EI (2010). “Afamelanotide”. Drugs of the Future. 35(5): 365.
Harms JH, Lautenschlager S, Minder CE, Minder EI, (2009). “Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone.” Photochem Photobiol 85(6):1434-9.
Harms, J et al., (2009), ‘An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria’, New Eng J Med. 360(3):306-307.
Barnetson R, et al, (2006). “[Nle4-D-Phe7]-alpha-Melanocyte-Stimulating Hormone Significantly Increased Pigmentation and Decreased UV Damage in Fair-Skinned Caucasian Volunteers.” Journal of Investigative Dermatology 126, 1869-1878.
Hadley ME, Dorr RT, (2006). “Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.” Peptides 27(4):921-30. E-Pub Jan 18.
Fitzgerald LM, Fryer JL, Dwyer T, Humphrey SM, (2006). “Effect of [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles.” Peptides 27(2):388-94. E-Pub 2005 Nov 15.
Dorr RT, et al, (2000). “Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans.” Photochem Photobiol 72(4):526-32.
Levine N, et al (1999). “Effects of a potent synthetic melanotropin, Nle4-D-Phe7-α-MSH (Melanotan-I) on tanning: a dose-ranging study.” Journal of Dermatological Treatment 10(2):127-32.

Over 200 articles have been published on afamelanotide (chemical name [Nle4, D-Phe7]α-MSH or NDP-MSH).